Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 8 5 W ELECTROLYTES versus TRAVASOL 5 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 8 5 W ELECTROLYTES versus TRAVASOL 5 5 SULFITE FREE W ELECTROLYTES IN PLASTIC CONTAINER.
AMINOSYN II 8.5% W/ELECTROLYTES vs TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and provide nitrogen for metabolic processes. Electrolytes maintain acid-base balance and osmotic pressure.
Travasol 5.5% with electrolytes provides a source of amino acids and electrolytes for parenteral nutrition, supporting protein synthesis and maintaining metabolic balance.
1 to 1.5 g amino acids/kg/day intravenously, typically infused over 12-24 hours.
Intravenous: 500 mL to 2 L per day, infused at a rate of 20-40 mL/kg/day (0.5-1.5 g amino acids/kg/day) based on metabolic needs and tolerance.
None Documented
None Documented
Variable; amino acids typically have half-lives of minutes to hours; free amino acids in plasma have t1/2 of 10-30 minutes for most
Not applicable; components are endogenous and rapidly cleared. Amino acids have short half-lives (e.g., alanine ~15 min; leucine ~30 min) and are continuously metabolized. Terminal elimination of water and electrolytes follows body fluid kinetics.
Renal >90% (as amino acids and metabolites); fecal <5%
Primarily renal; 90-100% eliminated as free amino acids, electrolytes, and water. Metabolized nitrogen is excreted as urea. Biliary/fecal: negligible (<2%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution